Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 9/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164285 | 1.00 | LSS (0.63) | LSSLMNACHRM4ACHEKDM4E | |
| SCHEMBL5202830 | 0.94 | LSS (0.65) | LSSLMNACHRM4ACHE | |
| SCHEMBL5202824 | 0.94 | LSS (0.65) | LSSLMNACHRM4ACHE | |
| SCHEMBL5164450 | 0.90 | LSS (0.51) | LSSLMNAACHEKDM4EF10 | |
| SCHEMBL5164456 | 0.90 | LSS (0.51) | LSSLMNAACHEKDM4EF10 | |
| SCHEMBL5025719 | 0.89 | LSS (0.68) | LSSLMNACHRM4ACHE | |
| SCHEMBL5025718 | 0.89 | LSS (0.68) | LSSLMNACHRM4ACHE | |
| SCHEMBL5166211 | 0.87 | LSS (0.57) | LSSLMNAACHE | |
| SCHEMBL5166206 | 0.87 | LSS (0.57) | LSSLMNAACHE | |
| SCHEMBL5165457 | 0.87 | LSS (0.63) | LSSLMNACHRM4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768658-A1 | HYDROXYALKYLAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | claimed |
| WO-2006125451-A1 | HYDROXYALKYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-30 | — | — | WO | claimed |
| US-6965048-B2 | Hydroxyalkylamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | claimed |
| US-20050009906-A1 | e.g., N-{4-[3-(4-Hydroxy-piperidin-1-yl)-3-oxo-propoxy]-cyclohexyl}-N-methyl-4-trifluoromethyl-benzenesulfonamide and p-chlorophenyl methyl-(2-{4-[methyl-(2-methylcarbamoyl-ethyl)-carbamoyl]-cyclohexyl}-ethyl)-carbamate | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-13 | — | — | US | claimed |
| EP-1768658-A1 | HYDROXYALKYLAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006125451-A1 | HYDROXYALKYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| US-6965048-B2 | Hydroxyalkylamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050009906-A1 | e.g., N-{4-[3-(4-Hydroxy-piperidin-1-yl)-3-oxo-propoxy]-cyclohexyl}-N-methyl-4-trifluoromethyl-benzenesulfonamide and p-chlorophenyl methyl-(2-{4-[methyl-(2-methylcarbamoyl-ethyl)-carbamoyl]-cyclohexyl}-ethyl)-carbamate | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009906-A1 | e.g., N-{4-[3-(4-Hydroxy-piperidin-1-yl)-3-oxo-propoxy]-cyclohexyl}-N-methyl-4-trifluoromethyl-benzenesulfonamide and p-chlorophenyl methyl-(2-{4-[methyl-(2-methylcarbamoyl-ethyl)-carbamoyl]-cyclohexyl}-ethyl)-carbamate | CYP51A1, CYP46A1, LSS | LSS 3/4885LMNA 1042/4885CHRM4 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.